Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone 1α,25-Dihydroxyvitamin D3
摘要:
A dozen 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D-3 were prepared, differing not only at the stereogenic sulfoximine stereocenter but also at the A-ring. Although these sulfoximines were not active transcriptionally and were only very weakly antiproliferative, some of them are powerful hydroxylase enzyme inhibitors. Specifically, 24-(S)-NH phenyl sulfoximine 3a is an extremely potent CYP24 inhibitor (IC50 = 7.4 nM) having low calcemic activity. In addition, this compound shows high selectivity toward the CYP24 enzyme in comparison to CYP27A1 (IC50 > 1000 nM) and CYP27B (IC50 = 554 nM).
Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone 1α,25-Dihydroxyvitamin D<sub>3</sub>
作者:Mehmet Kahraman、Sandra Sinishtaj、Patrick M. Dolan、Thomas W. Kensler、Sara Peleg、Uttam Saha、Samuel S. Chuang、Galina Bernstein、Bozena Korczak、Gary H. Posner
DOI:10.1021/jm040129+
日期:2004.12.1
A dozen 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D-3 were prepared, differing not only at the stereogenic sulfoximine stereocenter but also at the A-ring. Although these sulfoximines were not active transcriptionally and were only very weakly antiproliferative, some of them are powerful hydroxylase enzyme inhibitors. Specifically, 24-(S)-NH phenyl sulfoximine 3a is an extremely potent CYP24 inhibitor (IC50 = 7.4 nM) having low calcemic activity. In addition, this compound shows high selectivity toward the CYP24 enzyme in comparison to CYP27A1 (IC50 > 1000 nM) and CYP27B (IC50 = 554 nM).
[EN] 24-SULFOXIMINE VITAMIN D3 COMPOUNDS<br/>[FR] COMPOSES DE TYPE 24-SULFOXIMINE VITAMINE D3
申请人:UNIV JOHNS HOPKINS
公开号:WO2003106411A1
公开(公告)日:2003-12-24
The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1α,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.